Completed
Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet
NCT02238223
- Conditions
- Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases, +7 more
- Locations
-
Not specified